Ribociclib (LEE011)

For research use only. Not for use in humans.

製品コードS7440

Ribociclib (LEE011)化学構造

CAS No. 1211441-98-3

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

サイズ 価格(税別)  
JPY 34700
JPY 51300
JPY 86960
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(49)

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
特性 Orally bioavailable CDK4/6-selective inhibitor that has been tested in Phase III clinical trials for treatment of advanced breast cancer.
ターゲット
CDK4 [2]
(Cell-free assay)
CDK6 [2]
(Cell-free assay)
10 nM 39 nM
体外試験

LEE011, as dual CDK4/CDK6 inhibitor, significantly inhibits the growth of 12 of 17 neuroblastoma cell lines with mean IC50 of 307 nM. The growth inhibition of neuroblastoma cell lines is primarily cytostatic and is mediated by a G1 cell-cycle arrest and cellular senescence. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DFSP105 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTTdXlROjRiaB?= MWXHTVUxRTJ5NjDuUS=> NYLyUo9LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OVIxPThpPkK1PFUzODV6PD;hQi=>
Myoblast MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjofVQ4OiCq MWfJR|UxRTFyM{Wgcm0> NFjL[Y89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFM4PSd-MkW4NVA{PzV:L3G+
IMRS M1zUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC5cmo4OiCq NUXxW4JiUUN3ME24O|Mhdk1? NVjac5F5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
SKNAS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3TXZY4OiCq MmfETWM2OO,:nkGwNFAxKG6P MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMEO3OUc,OjV6MUCzO|U9N2F-
Rh28 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPUO|IhcA>? MlfGTWM2OD16NEWgcm0> NVHUfIdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
Rh41 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTO[Xo4OiCq MWTJR|UxRTdzOEegcm0> NHrCXmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFM4PSd-MkW4NVA{PzV:L3G+
CW9019 NWnYOpZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK3O|IhcA>? M3;4d2lEPTB;OUmxNkBvVQ>? MkDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
Rh5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKyO|IhcA>? M2rNcWlEPTExvK6xNFAxOCCwTR?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMEO3OUc,OjV6MUCzO|U9N2F-
Rh30 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonrO|IhcA>? Mn7nTWM2OO,:nkGwNFAxKG6P Moe3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
778 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XMNFczKGh? NYXFVZVqcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M3PpS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
449 M4np[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7zeoc4OiCq NVGxNIJscW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NED0eoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP3 M{\XSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\iO|IhcA>? MnX1bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NVu2V5RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
LP6 NGTXVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP4UVk4OiCq MWfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFzteY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP8 M3O5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXIb4FOPzJiaB?= M1W3T4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M4nldlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
LPS141 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDTRng4OiCq MlnUbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFfhcHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
778 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DXe|MvOzNizszN MUKyOEBp NHXDOVNl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
449 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTm[|c{NjN|IN88US=> M4G0TVI1KGh? NHHwbXFl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=> MkDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LP3 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT1e2M{NjN|IN88US=> MkXONlQhcA>? M4DQOYRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBUKHCqYYPl M2nXVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
LP6 NUi4So1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrpUoo{NjN|IN88US=> M1LWclI1KGh? NEXMZ45l\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LP8 NIrhWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CzdFMvOzNizszN MXSyOEBp M1r0XYRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBUKHCqYYPl MnziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LPS141 M1nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHSN{4{OyEQvF2= MXOyOEBp NXXTTIlJ\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKFNicHjhd4U> MlmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
IMR5 M2O0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LG[FI1KGh? NXG0e4ZDTE2VTx?= NFK0[GxKSzVyPUGyOkBvVQ>? M4rzZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
BE2C NGfpdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT0NlQhcA>? NFTxO3pFVVOR NGTaV3RKSzVyPUGzOEBvVQ>? NGT2NpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
1643 NHzKdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnMNlQhcA>? MUTEUXNQ M2\tZmlEPTB;MUS3JI5O NEfNTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
SKNSH MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP1NpA3OjRiaB?= M37weWROW09? M4XaemlEPTB;MUS4JI5O M4W4U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
SY5Y MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm3dVUzPCCq NIm2Z5FFVVOR NF;6emRKSzVyPUG1OEBvVQ>? M3T2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NGP MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7ldY8zPCCq M4LYPWROW09? MUTJR|UxRTF5NTDuUS=> M3PJ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
KELLY NWnWT49nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWeyOEBp NXfwZWdqTE2VTx?= NHKwfpFKSzVyPUKyNEBvVQ>? NVTW[HB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
CHP134 NGDkUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTLNlQhcA>? NHPDTWpFVVOR M1jBcmlEPTB;MkezJI5O Mmq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
NLF NFu5RXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXhNlQhcA>? MYTEUXNQ M2fnUGlEPTB;M{K4JI5O NH;ONVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
LAN5 M2O3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiyOEBp Mk[2SG1UVw>? NVvNbHc4UUN3ME20Nlkhdk1? NHnmRnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
NB69 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWyOEBp NFnFUm5FVVOR NXr0SHRVUUN3ME23N|ghdk1? M3K2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
SKNDZ NEfBV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:yOEBp NF\L[nNFVVOR MnnLTWM2OD16MEGgcm0> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
NBSD MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfuOm4zPCCq NYDZeFV2TE2VTx?= NILMPJhKSzVyPUG5NFAhdk1? MnP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
SKNF1 M1vyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKyOEBp NYfHTmJ4TE2VTx?= M2S5cmlEPTB;M{WwNEBvVQ>? NVHONXQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
EBC1 NVzHZW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTFWpkzPCCq NYr4NmE3TE2VTx?= MXXJR|UxRTZ2MECgcm0> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
SKNAS Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P4VFI1KGh? MXnEUXNQ NULufFFxUUN3MP-8olExODByIH7N NWO1fpFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
NB16 NUjteWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWyOEBp M3i2U2ROW09? M2D6e2lEPTExvK6xNFAxOCCwTR?= MkPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
RPE1 M1mwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorrNlQhcA>? NGDl[mRFVVOR M2m1SGlEPTExvK6xNFAxOCCwTR?= MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
Sf21 NGLrRZRHfW6ldHnvckBie3OjeR?= NInpNJoyOCCvaX7z NXfGNlFjUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBPNXSncn3pcoFtKEeVVD30ZYdo\WRiQ1TLOE9EgWOuaX6tSFMh[29vZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoMkGgZ4VtdHNidYPpcochWmJic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFupYX3tZVM{WF2DVGCgZYZ1\XJiMUCgcYlveyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODF|IN88UU4> Mm\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
Sf21 MoD5SpVv[3Srb36gZZN{[Xl? NH;GZ3MyOCCvaX7z NF3lVnJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGMufGW{bXnuZYwhPkircz30ZYdo\WRiQ1TLPU9EgWOuaX6tWFEh[29vZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoMkGgZ4VtdHNidYPpcochWESNdHnk[UB{fWK|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jM{PQYWFVWCCjZoTldkAyOCCvaX7zJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnegcYV1cG:mLDDJR|UxKD1iMD6xPVch|ryPLh?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
HepG2 NV;PSVRTSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NYnKcFlSPzJiaILz MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkK4OlIh|ryPLh?= M3HFdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO|k4PTxxYU6=
SEM MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{ftWVczKGi{cx?= NV6wOot7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IECuOFYxPSEQvF2u NGfvPIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO|k4PSd-Mkm0NFc6PzV:L3G+
KOPN8 NYf4c5NLSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mn3mO|IhcHK| MojURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNT2DOPEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR|UxKD1iMD61NFA5KM7:TT6= NUHzVHhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
NCI-H1299 M4nGdmN6fG:2b4jpZ4l1gSCjc4PhfS=> NXnxPGZWPzJiaILz NXTXdnR4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixNlk6KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDVwNE[g{txONg>? NVT2dVd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NVg{OTJpPkK5OVE5OzF{PD;hQi=>
T47D MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE\wS4c4OiCqcoO= NWXjT2czT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPi5{Mkeg{txONg>? M3rGd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
T47D M33BdWN6fG:2b4jpZ4l1gSCjc4PhfS=> NF;mcms4OiCqcoO= NEWxdWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IE[uNlMh|ryPLh?= NIK4d3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
H1299 M1y5cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlvkO|IhcHK| NH;zTYxIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJOTJ7OTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPy54M{eg{txONg>? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
KOPN8 NVTSPWRjSXCxcITvd4l{KGG|c3H5 NVjkWJRHOC53IIXN MUKzJIhzew>? NWLQNJRZUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDLU3BPQCClZXzsd{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4Yh[2ynYY\l[EBRSVKSIHzleoVtKGG2IECuOUB2VSCjZoTldkA{KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
KOPN8 MYXBdI9xfG:|aYOgZZN{[Xl? NYi0XHhVOC53IIXN MWCyOEBpenN? NETMfWVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFvPVG45KGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBkdGWjdnXkJHBCWlBibHX2[Ywh[XRiMD61JJVOKHC{ZT30doVifGWmIIfpeIghVkGFIH\vdkAyKGi{IHHu[EBu\WG|dYLl[EBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NEPBNpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO|k4PSd-Mkm0NFc6PzV:L3G+
Hep3B Mmq0R4VtdCCleXPs[UBie3OjeR?= NYnVVXlXOjRiaILz MnvrR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTIVxO0JiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdyL1exJJBp[XOnIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7 Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
HepG2 M{\pbmNmdGxiY4njcIUh[XO|YYm= NYnnXpZpOjRiaILz M3nQVWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG|ZTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eR?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
A549 MXnD[YxtKGO7Y3zlJIF{e2G7 MUOyOEBpenN? NVrSWHFPS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= MoDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
NCI-H460 MoTNR4VtdCCleXPs[UBie3OjeR?= MVOyOEBpenN? NGXhU2FE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBPS0lvSES2NEBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|AwTzFicHjhd4Uh[W[2ZYKgNlQhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpk> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
T47D MWrD[YxtKGO7Y3zlJIF{e2G7 NEO0UoczPCCqcoO= NV;DSIZsS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hXDR5RDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= MnvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
MDA-MB-231 NXSyUmZES2WubDDjfYNt\SCjc4PhfS=> MnrUNlQhcHK| M{D4cGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcxN0dzIIDoZZNmKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJ6 MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
Fluc-labeled 4T1 MWPBcpRqfHWvb4KgZZN{[Xl? MoLXNVMxKG2pL3vn NEnyRocyQCCmYYnz Mn;CRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViRnz1Z{1t[WKnbHXkJFRVOSClZXzsd{BqdXCuYX70[YQhcW5iQnHsZk9kKG2xdYPlJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjD0eY1weiC5ZXnnbJQh[XRiMUOwJI1oN2upLDDpdEBi\G2rbnnzeIVz\WRiZHHpcJkh\m:{IEG4JIRigXNibXXhd5Vz\WRiYX\0[ZIhQCC2bzCyOUBl[Xm| MoDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
T47D M2LlNWNmdGxiY4njcIUh[XO|YYm= NVHjXVBwOjRiaILz MUXJcoR2[3Srb36gc4Yh[2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hXDR5RDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBIOC:JMTDwbIF{\SCjY3P1cZVt[XSrb36gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliZnzve{BkgXSxbXX0dpk> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
pRb(S807) / Rb / p53 / Cyclin E / Cyclin D1 / CDK4 / CDK6 / p27 / p21 / PARP; 

PubMed: 29789630     


Effect of ribociclib on pRB and G1 cell cycle regulating protein expressions in C666-1 and HK1 cells. Cells were treated with ribociclib in 2 concentrations, one of them near their corresponding IC50, for 24 and 48 hours. Phosphorylation of Rb in all cell䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕

29789630
Growth inhibition assay
Cell viability ; 

PubMed: 26390342     


Effects of palbociclib and ribociclib on viability of H157, H2170, H520 and H596 cells after 72 hours of drug treatment and IC50 values for inhibition of cell viability.

26390342
体内試験

LEE011 (200 mg/kg daily, p.o.) significantly causes tumor growth delay in mice harboring the BE2C or 1643 xenografts with no weight loss or other signs of toxicity. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

- 合併
  • 細胞株: BE2C, IMR5, 1643, SY5Y, CHP134, SKNSH, NGP, KELLY, LAN5, NLF, NB69, SKNDZ, NBSD, NBLS, SKNFI, EBC1, SKNAS, NB16, RPE1 cell lines.
  • 濃度: 10 μM
  • 反応時間: ~100 hours
  • 実験の流れ:

    A panel of neuroblastoma cell lines, selected based upon prior demonstration of substrate adherent growth, is plated in triplicate on the Xcelligence Real-Time Cell Electronic Sensing system and treated 24 hours later with a four-log dose range of inhibitor or with a dimethyl sulfoxide (DMSO) control. Cell indexes are monitored continuously for ~100 hours, and IC50 values are determined as follows: growth curves are generated by plotting the cell index as a function of time and are normalized to the cell index at the time of treatment for a baseline cell index of 1. The area under the normalized growth curve from the time of treatment to 96 hours posttreatment is then calculated using a baseline area of 1 (the cell index at the time of treatment). Areas are normalized to the DMSO control, and the resulting data are analyzed using a nonlinear log inhibitor versus normalized response function. All experiments are repeated at least once.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: Mice bearing BE2C, NB-1643, or EBC1 xenografts.
  • 投薬量: ~200 mg/kg daily
  • 投与方法: p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 7 mg/mL (16.1 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 434.54
化学式

C23H30N8O

CAS No. 1211441-98-3
Storage powder
in solvent
別名 N/A
Smiles CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04657679 Not yet recruiting Drug: Ribociclib Breast Cancer Georgetown University|Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) December 2020 --
NCT04315233 Recruiting Drug: Ribociclib|Drug: Belinostat Metastatic Breast Cancer|Recurrent Ovarian Carcinoma University of Utah|Novartis|Acrotech Biopharma October 29 2020 Phase 1
NCT04417621 Recruiting Drug: LXH254|Drug: LTT462|Drug: Trametinib|Drug: Ribociclib Melanoma Novartis Pharmaceuticals|Novartis October 16 2020 Phase 2
NCT03834740 Recruiting Drug: Ribociclib|Drug: Everolimus Glioblastoma Multiforme|Glioma of Brain St. Joseph''s Hospital and Medical Center Phoenix|Ivy Brain Tumor Center|Barrow Neurological Institute December 21 2018 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

CDKシグナル伝達経路

相関CDK製品

Tags: Ribociclib (LEE011)を買う | Ribociclib (LEE011) ic50 | Ribociclib (LEE011)供給者 | Ribociclib (LEE011)を購入する | Ribociclib (LEE011)費用 | Ribociclib (LEE011)生産者 | オーダーRibociclib (LEE011) | Ribociclib (LEE011)化学構造 | Ribociclib (LEE011)分子量 | Ribociclib (LEE011)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID